Short Interest in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Declines By 20.1%

Key Points

• Short interest in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) decreased by 20.1% from July to August, with current short interest at 65,700 shares.
• Institutional investors currently own 30.11% of Brainsway stock, with several firms like Two Sigma Investments and Cubist Systematic Strategies recently increasing their stakes.
• The recent quarterly earnings reported an EPS of $0.10, beating expectations, and the stock has received upgraded ratings from brokers including Northland Securities and HC Wainwright.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report) saw a large drop in short interest in August. As of August 15th, there was short interest totaling 65,700 shares, a drop of 20.1% from the July 31st total of 82,200 shares. Based on an average daily volume of 57,100 shares, the short-interest ratio is presently 1.2 days. Based on an average daily volume of 57,100 shares, the short-interest ratio is presently 1.2 days.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC acquired a new position in Brainsway during the fourth quarter worth approximately $44,000. Raymond James Financial Inc. acquired a new position in Brainsway during the second quarter worth approximately $85,000. GAMMA Investing LLC increased its position in Brainsway by 720.7% during the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock worth $89,000 after buying an additional 8,216 shares during the period. Palumbo Wealth Management LLC acquired a new position in Brainsway during the first quarter worth approximately $111,000. Finally, Trexquant Investment LP acquired a new position in Brainsway during the first quarter worth approximately $129,000. Institutional investors and hedge funds own 30.11% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Brainsway in a research report on Monday, August 25th. Northland Securities raised their target price on Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a research report on Thursday, August 14th. Finally, Wall Street Zen raised Brainsway from a "hold" rating to a "buy" rating in a report on Sunday, August 17th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $18.00.

Brainsway Trading Up 0.4%

NASDAQ:BWAY traded up $0.07 during midday trading on Friday, hitting $15.77. 16,204 shares of the company were exchanged, compared to its average volume of 78,197. The company has a fifty day simple moving average of $13.48 and a 200 day simple moving average of $11.19. Brainsway has a fifty-two week low of $7.84 and a fifty-two week high of $16.25. The company has a market capitalization of $298.08 million, a PE ratio of 60.66 and a beta of 1.34.

Brainsway (NASDAQ:BWAY - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. The company had revenue of $12.63 million for the quarter, compared to analyst estimates of $12.34 million. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. Brainsway has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Brainsway will post 0.08 EPS for the current year.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.